Gabriele Antonarelli

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego et al. · The Lancet · 2024 · 69 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +4

Myeloid cell‐based delivery of IFN‐γ reprograms the leukemia microenvironment and induces anti‐tumoral immune responses

Adele Mucci, Gabriele Antonarelli, Carolina Caserta et al. · EMBO Molecular Medicine · 2021 · 28 citations · Full text

Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group

Gabriele Antonarelli, Chiara Corti, Paolo Andrea Zucali et al. · European Journal of Cancer · 2022 · 20 citations

Continuous Sunitinib Schedule, Medicine, Retrospective Analysis +7

Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development

Paolo Tarantino, Gabriele Antonarelli, Liliana Ascione et al. · Expert Opinion on Investigational Drugs · 2021 · 15 citations

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

Ilaria Attili, Carmine Valenza, Celeste Santoro et al. · Frontiers in Oncology · 2022 · 14 citations · Full text